In the second piece of news from Sweden today, Uppsala-based pharmaceutical company Orexo has acquired CePeP, founded on the back of research conducted by Prof Ulo Langel and his group at the Department of Neurochemistry, Stockholm University.
CePeP's technology platform is based on cell-penetrating peptides (CPPs), small peptide molecules that penetrate the cell membrane or act as "carriers" of other molecules that normally would not be able to get through this barrier. CPPs may be used to improve the delivery to cells of a large number of existing pharmaceutical products as well as offering a novel approach in drug discovery, according to Orexa.
"The ambition of Orexo is to utilize the CePeP technology for the development of new, improved pharmaceuticals. There is a strong strategic fit with the company's concept of fast development of clinically improved pharmaceuticals based on innovative drug delivery," said Björn Forsman, CEO of Orexo.
The financial terms of the acquisition have not been revealed, although Orexo did say that it was a shares-only transaction.